Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kringle PharmaTSE:4884 -5.00%40 PS Ratio is 31.02 as of Jul. 19, 2026, which is 5% above its 10-year median of 29.44. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円490.85 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Kringle Pharma ranks worse than 73.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kringle Pharma's share price is 円323.00.
Kringle Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円10.41. Hence, Kringle Pharma's PS Ratio for today is 31.02.
Good Sign:
Kringle Pharma Inc stock PS Ratio (=31.02) is close to 2-year low of 29.1.
The historical rank and industry rank for Kringle Pharma's PS Ratio or its related term are showing as below:
TSE:4884'
s PS Ratio Range Over the Past 10 Years
Min: 5.73 Med: 29.44 Max: 174.48
Current: 31.02
During the past 8 years, Kringle Pharma's highest PS Ratio was 174.48. The lowest was 5.73. And the median was 29.44.
TSE:4884's PS Ratio is ranked worse than 73.47% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs TSE:4884: 31.02
Kringle Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Kringle Pharma was 8.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -49.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -51.70% per year.
During the past 8 years, Kringle Pharma's highest 3-Year average Revenue per Share Growth Rate was -43.60% per year. The lowest was -68.80% per year. And the median was -49.20% per year.
Back to Basics: PS Ratio
Kringle Pharma (TSE:4884) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Kringle Pharma PS Ratio Related Terms
Kringle Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kringle Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kringle Pharma's Share Price of today is 円323.00. Kringle Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円10.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kringle Pharma (TSE:4884) has a PS Ratio of 31.02 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kringle Pharma and its competitors. This is near median its historical median of 29.44. Over the past decade, Kringle Pharma's PS Ratio has ranged from 5.73 to 174.48. According to the industry distribution chart, Kringle Pharma ranks #684 out of 931 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Kringle Pharma's PS Ratio too high?
Kringle Pharma's current PS Ratio of 31.02 is near median its 10-year median of 29.44. Over the past 10 years, this metric has ranged from a low of 5.73 to a high of 174.48. The Biotechnology industry median PS Ratio is 9.32. Kringle Pharma's value of 31.02 is 232.8% above this industry median. Based on the distribution chart, Kringle Pharma ranks #684 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #684 out of 931 companies for PS Ratio. This places Kringle Pharma in the lower half of its industry. The industry median PS Ratio is 9.32. Kringle Pharma's value of 31.02 is 232.8% above this benchmark. Historically, Kringle Pharma's own PS Ratio has ranged from 5.73 to 174.48 over the past decade. While the company's 10-year median is 29.44 vs. the industry median of 9.32, Kringle Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kringle Pharma's current PS Ratio of 31.02 is 232.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kringle Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kringle Pharma's current PS Ratio is 31.02, which is near median its own 10-year median of 29.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円490.85, compared to a current price of 円323.00 — trading 34.2% below its estimated fair value. The current PS Ratio is 31.02, which is near median its 10-year median of 29.44 and 232.8% above the Biotechnology industry median of 9.32. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current PS Ratio is 31.02 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円323.00 is trading 34.2% below its estimated GF Value™ of 円490.85.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
PS Ratio: 31.02 (near median its 10-year median of 29.44)
GF Value™: 円490.85 vs. price of 円323.00 (34.2% below fair value)
Industry Position: 232.8% above the Biotechnology median (#684 of 931)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score
Get the complete analysis for TSE:4884
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
